Differential effects of ibogaine pretreatment on brain levels of morphine and (+)-amphetamine.
Stanley D Glick, C A Gallagher, L B Hough, K L Rossman, Isabelle M Maisonneuve
Brain Research August 14, 1992 DOI: 10.1016/0006-8993(92)91360-q (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Experimental study Peer reviewed |
|---|---|
| Population | Rats |
| Intervention | Ibogaine pretreatment |
| Duration | 19 h pretreatment, measurements at 30 min and 2 h after injection |
| Topics | Ibogaine |
| Citations | 21 |
| Key findings | Ibogaine pretreatment increased brain amphetamine levels but had no effect on brain morphine levels, suggesting a hepatic drug-drug interaction underlies ibogaine's interaction with amphetamine but not with morphine. |
Abstract
Previous studies in rats have shown that ibogaine inhibits neurochemical and behavioral effects of morphine yet potentiates similar effects of (+)-amphetamine. To assess whether these different functional interactions have a metabolic basis, brain levels of morphine and (+)-amphetamine were measured by gas chromatography-mass spectrometry after ibogaine pretreatment (19 h before injection of morphine or (+)-amphetamine). Ibogaine pretreatment had no effect on brain morphine levels, either at 30 min or 2 h after morphine injection; however, ibogaine significantly increased brain amphetamine levels at 30 min and, to a greater extent, at 2 h after (+)-amphetamine injection. These and other data suggest that ibogaine irreversibly inhibits an amphetamine-metabolizing enzyme. The functional interactions between ibogaine and (+)-amphetamine, but not those between ibogaine and morphine, may result from a hepatic drug-drug interaction.